Phathom Pharmaceuticals (PHAT) Interest Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Interest Expenses data on file, last reported at $34.2 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 89.42% year-over-year to $34.2 million in Q1 2026; TTM through Mar 2026 was $34.2 million, a 52.19% decrease from a year earlier, with the FY2025 full-year figure at $80.5 million, down 68.47% from the prior year.
• Interest Expenses for Q1 2026 stood at $34.2 million, up from $16.4 million in the prior quarter.
• Over the last five years, Interest Expenses for PHAT reached as high as $51.6 million in Q3 2024 and fell as low as $2.8 million in Q1 2022.
• Historically, Interest Expenses has averaged $19.4 million across 5 years, with a median of $17.2 million in 2024.
• Across the five-year window, Interest Expenses plunged 83.62% in 2022 and soared 788.05% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $3.8 million in 2022, then soared by 788.05% to $33.7 million in 2023, then tumbled by 44.9% to $18.6 million in 2024, then declined by 11.69% to $16.4 million in 2025, then soared by 108.48% to $34.2 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $34.2 million in Q1 2026, $16.4 million in Q4 2025, and $41.4 million in Q3 2025.